DBV Technologies reported 284.98M in Assets for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Assets Change
DBV Technologies DBVT:US 284.98M 167.4M
Acadia Pharmaceuticals ACAD:US $ 612.77M 11.48M
Alnylam Pharmaceuticals ALNY:US $ 3330.42M 103.13M
Amarin AMRN:US $ 973.24M 0.47M
Biocryst Pharmaceuticals BCRX:US $ 510.54M 17.18M
Biomarin Pharmaceutical BMRN:US $ 6145.84M 83.13M
Eleven Biotherapeutics EBIO:US $ 225.84M 14.91M
Esperion Therapeutics ESPR:US $ 303.98M 38.87M
Galectin Therapeutics GALT:US $ 25.89M 7.73M
Halozyme Therapeutics HALO:US $ 1781.39M 619.14M
Insmed INSM:US $ 1.05B 99.96M
Intercept Pharmaceuticals ICPT:US $ 498.6M 4.76M
IONIS PHARMACEUT IONS:US $ 2456.13M 62.96M
Neurocrine Biosciences NBIX:US $ 2005.7M 138.8M
Ptc Therapeutics PTCT:US $ 1804.06M 4.47M
Sarepta Therapeutics SRPT:US $ 2996.85M 59.3M
Ultragenyx Pharmaceutical RARE:US $ 1320.63M 63.4M
United Therapeutics UTHR:US $ 5543.3M 183.5M
YTE INCY:US $ 5319.04M 264.81M